KR102103701B1 - 전립선암 치료용 항-알파-ｖ 인테그린 항체 - Google Patents

전립선암 치료용 항-알파-ｖ 인테그린 항체 Download PDF

Info

Publication number
KR102103701B1
KR102103701B1 KR1020197011392A KR20197011392A KR102103701B1 KR 102103701 B1 KR102103701 B1 KR 102103701B1 KR 1020197011392 A KR1020197011392 A KR 1020197011392A KR 20197011392 A KR20197011392 A KR 20197011392A KR 102103701 B1 KR102103701 B1 KR 102103701B1
Authority
KR
South Korea
Prior art keywords
treatment
di17e6
patients
patient
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020197011392A
Other languages
English (en)
Korean (ko)
Other versions
KR20190044696A (ko
Inventor
악셀 호프만
하인리히 란네르트
클라우스 브리슈바인
프레데릭 크리슈티안 피프
위르겐 라인들
카린 그롤
미하엘 췰스도르프
오트마르 파프
자비네 라브
울리케 다우
베누아 데스뜨나브
Original Assignee
메르크 파텐트 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 메르크 파텐트 게엠베하 filed Critical 메르크 파텐트 게엠베하
Publication of KR20190044696A publication Critical patent/KR20190044696A/ko
Application granted granted Critical
Publication of KR102103701B1 publication Critical patent/KR102103701B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2848—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Cell Biology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020197011392A 2011-02-11 2012-02-07 전립선암 치료용 항-알파-ｖ 인테그린 항체 Expired - Fee Related KR102103701B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11001135 2011-02-11
EP11001135.0 2011-02-11
PCT/EP2012/000548 WO2012107211A1 (en) 2011-02-11 2012-02-07 Anti-alpha-v integrin antibody for the treatment of prostate cancer

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020137023946A Division KR101972533B1 (ko) 2011-02-11 2012-02-07 전립선암 치료용 항-알파-ｖ 인테그린 항체

Publications (2)

Publication Number Publication Date
KR20190044696A KR20190044696A (ko) 2019-04-30
KR102103701B1 true KR102103701B1 (ko) 2020-04-23

Family

ID=45569571

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020137023946A Expired - Fee Related KR101972533B1 (ko) 2011-02-11 2012-02-07 전립선암 치료용 항-알파-ｖ 인테그린 항체
KR1020197011392A Expired - Fee Related KR102103701B1 (ko) 2011-02-11 2012-02-07 전립선암 치료용 항-알파-ｖ 인테그린 항체

Family Applications Before (1)

Application Number Title Priority Date Filing Date
KR1020137023946A Expired - Fee Related KR101972533B1 (ko) 2011-02-11 2012-02-07 전립선암 치료용 항-알파-ｖ 인테그린 항체

Country Status (23)

Country Link
US (3) US9555110B2 (enExample)
EP (2) EP2672994B1 (enExample)
JP (2) JP6320042B2 (enExample)
KR (2) KR101972533B1 (enExample)
CN (1) CN103347540B (enExample)
AU (2) AU2012216145B2 (enExample)
CA (1) CA2827052C (enExample)
DK (1) DK2672994T3 (enExample)
EA (1) EA032117B1 (enExample)
ES (1) ES2683347T3 (enExample)
HR (1) HRP20181212T1 (enExample)
HU (1) HUE037212T2 (enExample)
IL (1) IL227687B (enExample)
LT (1) LT2672994T (enExample)
MX (2) MX352025B (enExample)
PL (1) PL2672994T3 (enExample)
PT (1) PT2672994T (enExample)
RS (1) RS57524B1 (enExample)
SG (1) SG192667A1 (enExample)
SI (1) SI2672994T1 (enExample)
TR (1) TR201810294T4 (enExample)
WO (1) WO2012107211A1 (enExample)
ZA (1) ZA201306807B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR201810294T4 (tr) 2011-02-11 2018-08-27 Merck Patent Gmbh Prostat kanseri tedavisi için anti-alfa-v integrin antikoru.
KR20170052690A (ko) 2014-09-17 2017-05-12 메르크 파텐트 게엠베하 고형암 및/또는 이의 전이 치료 방법, 그에 따른 약제, 및 고형암 및/또는 이의 전이 치료의 임상 결과 예측 방법
ES2897782T3 (es) * 2014-09-17 2022-03-02 Merck Patent Gmbh Método de tratamiento de las enfermedades de la metástasis ósea, medicamentos para el tratamiento y método para predecir el resultado clínico del tratamiento de las enfermedades causadas por metástasis ósea
US20190144547A1 (en) 2015-11-23 2019-05-16 Merck Patent Gmbh Anti-alpha-v integrin antibody for the treatment of fibrosis and/or fibrotic disorders
TW201720843A (zh) * 2015-11-23 2017-06-16 馬克專利公司 用於治療纖維化及／或纖維化病症之抗－αＶ整合素抗體
WO2024137442A1 (en) 2022-12-21 2024-06-27 Gilead Sciences, Inc. Combination therapy for treating cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009010290A2 (en) * 2007-07-17 2009-01-22 Merck Patent Gmbh Engineered anti-alpha v- integrin hybrid antibodies

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ282603B6 (cs) 1991-03-06 1997-08-13 Merck Patent Gesellschaft Mit Beschränkter Haftun G Humanizované a chimerické monoklonální protilátky
US5753230A (en) 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
EP0719859B1 (en) 1994-12-20 2003-07-02 MERCK PATENT GmbH Anti-alpha V-integrin monoclonal antibody
DE19534177A1 (de) 1995-09-15 1997-03-20 Merck Patent Gmbh Cyclische Adhäsionsinhibitoren
GB2339430A (en) 1997-05-21 2000-01-26 Biovation Ltd Method for the production of non-immunogenic proteins
DE19842415A1 (de) 1998-09-16 2000-03-23 Merck Patent Gmbh Pharmazeutische Zubereitung
DE69934967T2 (de) 1998-12-08 2007-12-06 Biovation Ltd. Verfahren zur verminderung der immunogenität von proteinen
US7163681B2 (en) * 2000-08-07 2007-01-16 Centocor, Inc. Anti-integrin antibodies, compositions, methods and uses
EP1998266A3 (en) 2001-02-19 2009-02-11 Merck Patent GmbH Method for identification of T-cell epitopes and use for preparing molecules with reduced immunogenicity
DE10163459A1 (de) 2001-12-21 2003-07-03 Merck Patent Gmbh Lyophilisierte Zubereitung enthaltend Antikörper gegen EGF-Rezeptor
NZ540562A (en) 2002-11-26 2008-04-30 Pdl Biopharma Inc Therapeutic chimeric and humanized antibodies directed against alpha5beta1 integrin, methods for purification of these antibodies, and their use in treating conditions comprising undesirable tissue angiogenesis
US8147832B2 (en) 2003-08-14 2012-04-03 Merck Patent Gmbh CD20-binding polypeptide compositions and methods
AU2005211890B2 (en) 2004-02-12 2011-07-28 Merck Patent Gmbh Highly concentrated liquid formulations of anti-EGFR antibodies
KR20060002667A (ko) 2004-07-03 2006-01-09 삼성전자주식회사 디스크 댐퍼와 디스크 프로텍터를 구비한 하드 디스크드라이브
US8202465B2 (en) 2004-11-03 2012-06-19 Honeywell International Inc. Preferential curing technique in compression molding of fiber reinforced composites
US20070025889A1 (en) 2005-07-28 2007-02-01 Pcbu Business Services, Inc. Reactors, reactor assemblies and production processes
DE102005062440B4 (de) 2005-12-27 2011-02-24 Lts Lohmann Therapie-Systeme Ag Proteinbasiertes Trägersystem zur Resistenzüberwindung von Tumorzellen
DK2270050T3 (da) 2005-12-30 2013-08-12 Merck Patent Gmbh Anti-CD19-antistoffer med nedsat immunogenicitet
ES2521679T3 (es) 2006-01-18 2014-11-13 Merck Patent Gmbh Terapia específica usando ligandos de integrinas para el tratamiento del cáncer
US8715718B2 (en) 2006-07-14 2014-05-06 Rutgers, The State University Of New Jersey Extracellular matrix production from nanoscale substrate
US20110177155A1 (en) 2007-08-21 2011-07-21 Immune Disease Institute, Inc. Methods of delivery of agents to leukocytes and endothelial cells
US20120004129A1 (en) 2008-12-23 2012-01-05 Merck Patent Gmbh Biomarkers for inhibitors with anti-angiogenic activity
CA2771441C (en) 2009-08-19 2016-10-11 Merck Patent Gmbh Antibodies for the detection of integrin complexes in ffpe material
US20120263739A1 (en) 2009-11-13 2012-10-18 Merck Patent Gmbh Anti integrin antibodies linked to nanoparticles loaded with chemotherapeutic agents
WO2011162933A1 (en) * 2010-06-04 2011-12-29 Immunogen, Inc. Anti-integrin immunoconjugate dosing regimens
TR201810294T4 (tr) 2011-02-11 2018-08-27 Merck Patent Gmbh Prostat kanseri tedavisi için anti-alfa-v integrin antikoru.
JP6035716B2 (ja) 2011-08-26 2016-11-30 ソニー株式会社 情報処理システム及び情報処理方法
WO2014143383A1 (en) 2013-03-13 2014-09-18 Agilent Technologies, Inc. Transposome tethered to a gene delivery vehicle
EP3041863A4 (en) 2013-09-05 2017-08-16 Amgen Inc. Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009010290A2 (en) * 2007-07-17 2009-01-22 Merck Patent Gmbh Engineered anti-alpha v- integrin hybrid antibodies

Also Published As

Publication number Publication date
IL227687A0 (en) 2013-09-30
EP2672994A1 (en) 2013-12-18
HRP20181212T1 (hr) 2018-10-05
US20170218070A1 (en) 2017-08-03
AU2017200998B2 (en) 2018-08-09
CA2827052C (en) 2022-08-16
KR101972533B1 (ko) 2019-08-26
MX385144B (es) 2025-03-14
PT2672994T (pt) 2018-10-22
CA2827052A1 (en) 2012-08-16
EP2672994B1 (en) 2018-05-09
SG192667A1 (en) 2013-09-30
ES2683347T3 (es) 2018-09-26
DK2672994T3 (en) 2018-07-16
AU2012216145A1 (en) 2013-09-26
EA032117B1 (ru) 2019-04-30
KR20140012087A (ko) 2014-01-29
ZA201306807B (en) 2014-05-28
IL227687B (en) 2019-02-28
JP2017066156A (ja) 2017-04-06
AU2012216145B2 (en) 2016-11-17
TR201810294T4 (tr) 2018-08-27
EP3415162A1 (en) 2018-12-19
MX352025B (es) 2017-11-07
WO2012107211A1 (en) 2012-08-16
US20140086908A1 (en) 2014-03-27
CN103347540A (zh) 2013-10-09
KR20190044696A (ko) 2019-04-30
AU2017200998A1 (en) 2017-03-09
JP6488273B2 (ja) 2019-03-20
EA201391147A1 (ru) 2014-01-30
PL2672994T3 (pl) 2018-11-30
US20190263913A1 (en) 2019-08-29
US9555110B2 (en) 2017-01-31
RS57524B1 (sr) 2018-10-31
CN103347540B (zh) 2016-05-25
HK1190094A1 (zh) 2014-06-27
LT2672994T (lt) 2018-07-25
JP2014510047A (ja) 2014-04-24
MX2013009062A (es) 2013-10-01
HUE037212T2 (hu) 2018-08-28
JP6320042B2 (ja) 2018-05-09
SI2672994T1 (sl) 2018-09-28

Similar Documents

Publication Publication Date Title
JP4364510B2 (ja) 受容体型チロシンキナーゼ阻害剤および血管新生阻害剤を用いる併用療法
AU2017200998B2 (en) Anti-alpha-v integrin antibody for the treatment of prostate cancer
KR20080089489A (ko) 인테그린 리간드를 사용하는 암치료용 특이적 요법
AU2002219221A1 (en) Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors
CZ20033226A3 (en) Combination therapy using anti-egfr antibodies and anti-hormonal agents
KR20080110987A (ko) 항-ｅｇｆｒ 및 항-ｈｅｒ２ 항체를 이용하는 조합 요법
KR20230018454A (ko) 항-c-Met 항체-약물 접합체 및 이의 용도
ZA200309060B (en) Combination therapy using anit-angiogenic agents and TNFalpha.
JP2012528079A (ja) 癌を治療するためのインテグリンリガンドの連続投与
JP2015502975A (ja) ヒト成長ホルモン受容体アンタゴニスト抗体およびその使用方法
TW202003577A (zh) 用於在未曾接受過治療之個體治療癌症的標靶性TGF-β抑制之給藥方案
KR20080089645A (ko) 암의 적출 장기 관류 병용 요법
HK1190094B (en) Anti-alpha-v integrin antibody for the treatment of prostate cancer

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

St.27 status event code: A-0-1-A10-A18-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

Fee payment year number: 1

St.27 status event code: A-2-2-U10-U12-oth-PR1002

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PC1903 Unpaid annual fee

Not in force date: 20230418

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

St.27 status event code: A-4-4-U10-U13-oth-PC1903

PC1903 Unpaid annual fee

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20230418

St.27 status event code: N-4-6-H10-H13-oth-PC1903